The Asia Cornea Society Infectious Keratitis Study (ACSIKS)
Corneal diseases are a major cause of blindness worldwide, and corneal infections are a substantial cause of blindness in Asia. The aim of the Asia Cornea Society Infectious Keratitis Study (ACSIKS) is to study infectious keratitis (corneal infections) in Asian countries, so as to improve strategies for prevention and treatment, and to reduce the burden of blindness in Asia.
The first phase of ACSIKS is an 18-month observational study involving 11 eye hospitals in 8 Asian countries; these hospitals manage more than 6700 cases of corneal infections every year. From the first quarter of 2012, all patients with a corneal infection will be recruited and a standard ACSIKS protocol will be applied; this protocol includes the use of a common set of study forms and a suggested panel of microbiological examinations. However, each centre will be continue to treat their patients with the anti-infective therapy standard for their centre. Data will be recorded for each patient for a period of six months, including their medical and surgical management, the final clinical outcome and vision.
Bacterial and fungal growths from patients will also be stored for further research during a second phase of ACSIKS. These studies will focus on evaluating the resistance of the most common bacterial infections to the current available antibiotics, performing DNA testing to compare our strains with bacterial infections in the West, and to developing new diagnostic tests and anti-infective therapies tailored to corneal infections in Asia.
|Study Design:||Observational Model: Case-Only
Time Perspective: Prospective
|Official Title:||The Asia Cornea Society Infectious Keratitis Study|
- Resolution of infectious keratitis [ Time Frame: 6 months from enrollment ] [ Designated as safety issue: No ]Resolution of the infectious keratitis occurs when the infiltrate clears, epithelium heals over, and inflammation subsides.
- Number of acute surgical interventions required. [ Time Frame: 6 months from enrollment ] [ Designated as safety issue: No ]Any form of surgery performed during the acute stage of the infection. The number and type of surgery performed and the surgical outcomes will be captured.
- Visual acuity outcome of management. [ Time Frame: 6 months from enrollment ] [ Designated as safety issue: No ]Visual acuity will be documented. Reasons for poor visual acuity (less than 6/18 or 0.3) will be recorded.
Biospecimen Retention: Samples Without DNA
Positive bacterial and fungal growth obtained from the cornea samples of ACSIKS patients will be retained and stored.
|Study Start Date:||April 2012|
|Estimated Study Completion Date:||October 2013|
|Estimated Primary Completion Date:||October 2013 (Final data collection date for primary outcome measure)|
Summary of the ACSIKS Clinical Protocol:
All patients with an initial clinical diagnosis of infectious keratitis will be referred by the attending ophthalmologist-in-charge to an ACSIKS co-investigator or trial coordinator for recruitment into the study. Patients will be enrolled in the study after study informed consent is obtained and a trained interviewer will administer a standardized ACSIKS Clinical Case Report Form to each recruited subject. Information that will be documented would include the demographic profile (e.g. age, gender, ethnic group, occupation, etc), risk factors for infectious keratitis, presenting symptoms and prior treatment.
Patients who are contact lens wearers will also complete a separate contact lens questionnaire, with specific questions on duration of contact lens wear, type of contact lens and solutions used, lens wear schedule and habits, and adherence to lens care practices.
All patients will undergo a thorough ocular examination by the ophthalmologist-in-charge or an ACSIKS co-investigator, and details of the infectious keratitis and associated findings documented on the ACSIKS Clinical CRF. With the approval of the ophthalmologist-in-charge, corneal scrapings will then be collected as per the ACSIKS Microbiological Protocol. Each study subject will consequently still be managed by the ophthalmologist-in-charge according to his/her current clinical approach, with appropriate medical or surgical treatment carried out in accordance with the practice patterns and standards of his/her institution, and no attempt to deviate from current treatment practices.
Regular chart reviews will be performed by ACSIKS trial coordinators for the six months duration of the subjects' involvement to document the initial differential diagnoses and medical treatment, the microbiological results, and any changes to the diagnosis and treatment. The last consultation with the ophthalmologist-in-charge during that six month-period will be taken as the final study review.
Summary of the ACSIKS Microbiological Protocol:
At the discretion of the ophthalmologist-in-charge, corneal scrapings will be collected based on a list of investigations suggested by the ACSIKS Group.
All microbiological specimens will be incubated, interpreted and reported according to agreed upon common standards, regardless of the number of colonies present. Bacterial organisms will also be tested using standardized antibiograms agreed upon by microbiologists from the various participating institutions. Results of any and all microbiological testing will be collected and recorded into the ACSIKS Microbiological Case Report Form.
If these samples do yield a positive growth of either fungal or bacterial organisms (or both), the causative organisms cultured will be sub-cultured and stored at each site's ACSIKS freezer, for subsequent transport to the ACSIKS Central Repository in Singapore for use in future microbial studies under Phase 2 of the ACSIKS project.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01560208
|Shandong Eye Institute||Recruiting|
|Qingdao, China, 266071|
|Contact: Lixin Xie, MD firstname.lastname@example.org|
|Principal Investigator: Lixin Xie|
|Xiamen Eye Center||Recruiting|
|Contact: Li Wei email@example.com|
|Principal Investigator: Zuguo Liu|
|L.V.Prasad Eye Institute||Recruiting|
|Hyderabad, Andhra Pradesh, India, 500 034|
|Contact: Prashant Garg firstname.lastname@example.org|
|Principal Investigator: Prashant Garg|
|Aravind Eye Hospital||Recruiting|
|Madurai, Tamil Nadu, India, 625 020|
|Contact: Sean D'Silva email@example.com|
|Principal Investigator: Venkatesh Prajna|
|Department of Ophthalmology, Faculty of Medicine, Osaka University Graduate School of Medicine Hospital||Recruiting|
|Osaka, Japan, 565-0871|
|Contact: Takeshi Soma firstname.lastname@example.org|
|Principal Investigator: Kohji Nishida|
|Department of Ophthalmology, Tottori University Hospital||Recruiting|
|Tottori, Japan, 683-8504|
|Contact: Chizu Touge email@example.com|
|Principal Investigator: Yoshitsugu Inoue|
|Korea, Republic of|
|Department of Opthalmology & Visual Science, The Catholic University of Korea, Seoul St. Mary's Eye Institute||Recruiting|
|Seoul, Korea, Republic of, 137-701|
|Contact: Choun-Ki Joo firstname.lastname@example.org|
|Principal Investigator: Choun-Ki Joo|
|Department of Ophthalmology and Visual Sciences, Philippine General Hospital||Recruiting|
|Manila, Philippines, 1223|
|Contact: Denise Mae Palmos email@example.com|
|Principal Investigator: Ma Dominga B Padilla|
|Singapore Eye Research Institute||Recruiting|
|Singapore, Singapore, 168751|
|Contact: Abriena Xie firstname.lastname@example.org|
|Principal Investigator: Jodhbir Mehta|
|Department of Opthalmology, National Taiwan University Hospital||Recruiting|
|Taipei City, Taiwan, 100|
|Contact: Stephanie Chu email@example.com|
|Principal Investigator: Fung Rong Hu|
|Department of Ophthalmology, Faculty of Medicine, Siriraj Hospital, Mahidol University||Recruiting|
|Bangkok, Thailand, 10700|
|Contact: Pormsiri Chinawangwatarnakrnl firstname.lastname@example.org|
|Principal Investigator: Panida Goseyarakwong|
|Principal Investigator:||Donald TH Tan, FRCS(G)||Singapore National Eye Centre, Singapore Eye Research Institute, National University Hospital|